Loading...
XHKG1061
Market cap215mUSD
Dec 23, Last price  
2.95HKD
1D
6.12%
1Q
28.82%
Jan 2017
-11.41%
Name

Essex Bio-Technology Ltd

Chart & Performance

D1W1MN
XHKG:1061 chart
P/E
6.08
P/S
0.98
EPS
0.49
Div Yield, %
2.39%
Shrs. gr., 5y
-0.19%
Rev. gr., 5y
7.72%
Revenues
1.71b
+29.51%
38,906,92849,197,29182,789,684152,674,582214,070,523116,688,187146,281,574212,716,340267,255,167347,046,987518,299,695654,010,499775,662,998899,589,7291,176,457,9311,279,478,212978,111,1261,637,659,4311,317,710,6161,706,556,141
Net income
275m
+22.11%
7,604,63915,547,7533,763,27711,001,92621,826,71011,550,88926,584,37233,202,62838,995,13654,896,69675,273,091104,895,190136,284,381167,298,653231,091,674302,502,420218,925,555345,968,083225,411,310275,259,617
CFO
339m
-11.39%
2,831,982-2,224,8804,403,899-5,786,1943,746,69746,631,16328,123,45223,380,40935,788,51765,119,10334,922,49168,640,46585,278,686193,720,031200,872,681232,858,075299,238,146409,161,400382,785,659339,205,269
Dividend
Sep 09, 20240.06 HKD/sh
Earnings
May 28, 2025

Profile

Essex Bio-Technology Limited, an investment holding company, develops, manufactures, distributes, and sells biopharmaceutical products in the People's Republic of China and internationally. The company operates through Ophthalmic Products and Surgical Products segments. It researches and develops basic fibroblast growth factor products for the treatment of cellular proliferation, differentiation, and migration. The company offers Beifushu series, such as Beifushu eye drops, Beifushu eye gel, and Beifushu unit-dose eye drops; Tobramycin eye drops, Levofloxacin eye drops, and Sodium Hyaluronate eye drops, as well as Iodized Lecithin Capsules. It also provides Beifuji sprays and lyophilized powder, and Beifuxin gels for use in burn and scald wounds, acute wounds, surgical incisions, chronic wounds, skin grafting, and other applications. In addition, it offers ophthalmic and surgical products from third parties. Further, the company offers Carisolv dental caries removal gel; and Yi Xue An Granules. It has license agreements with Mitotech S.A. and Mitotech LLC. The company was founded in 1990 and is headquartered in Zhuhai, China.
URL
http://www.essexbio.com/
IPO date
Jun 27, 2001
Employees
1,462
Domiciled in
HK
Incorporated in
KY

Valuation

Title
HKD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
1,706,556
29.51%
1,317,711
-19.54%
1,637,659
67.43%
Cost of revenue
1,435,371
1,066,079
1,255,125
Unusual Expense (Income)
NOPBT
271,185
251,632
382,534
NOPBT Margin
15.89%
19.10%
23.36%
Operating Taxes
70,755
34,931
48,489
Tax Rate
26.09%
13.88%
12.68%
NOPAT
200,430
216,701
334,045
Net income
275,260
22.11%
225,411
-34.85%
345,968
58.03%
Dividends
(39,921)
(54,526)
(51,889)
Dividend yield
Proceeds from repurchase of equity
(12,593)
(14,790)
(6,794)
BB yield
Debt
Debt current
237,561
107,613
155,915
Long-term debt
78,562
384,689
414,600
Deferred revenue
382,121
406,489
Other long-term liabilities
(382,121)
(406,489)
Net debt
(239,265)
(79,094)
(157,397)
Cash flow
Cash from operating activities
339,205
382,786
409,161
CAPEX
(21,031)
(282,913)
(244,533)
Cash from investing activities
(54,338)
(302,030)
(280,084)
Cash from financing activities
(309,925)
(169,110)
(73,132)
FCF
115,777
306,422
262,883
Balance
Cash
515,025
543,492
671,350
Long term investments
40,363
27,904
56,562
Excess cash
470,060
505,510
646,029
Stockholders' equity
1,850,498
1,677,230
1,660,984
Invested Capital
1,747,739
1,678,613
1,588,526
ROIC
11.70%
13.27%
22.76%
ROCE
12.03%
11.32%
16.89%
EV
Common stock shares outstanding
595,646
599,388
602,005
Price
Market cap
EV
EBITDA
331,061
293,545
415,505
EV/EBITDA
Interest
11,212
11,472
9,225
Interest/NOPBT
4.13%
4.56%
2.41%